ddI and Portal Hypertension

The FDA has concluded that ddI use is associated with the development of noncirrhotic portal hypertension. Forty-two cases have been reported, including several that led . . .

The FDA has concluded that ddI use is associated with the development of noncirrhotic portal hypertension. Forty-two cases have been reported, including several that led to liver transplantation or death. Clinicians are being urged to monitor ddI recipients for early signs of this condition.